Review Article

Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia

Table 1

Anti-CML TKIs.

TKIsCompound namePrevious nameCompanyTrade nameApproval by US, FDADosage

First-generation TKIImatinibSTI571, CPG57148BNovartisGleevac or Glivec2001CML-CP-400 mg once daily

Second-generation TKIsNilotinibAMN107NovartisTasigna2006CML-
CP/AP-400 mg twice daily
DasatinibBMS354825Bristol-Myers SquibbSprycel2007CML-CP-100 mg once daily
BosutinibSKI606PfizerBosulif2012500 mg once daily

Third-generation TKIPonatinibAP24534AriadIclusig201345 mg once daily

CP: chronic phase; AP: accelerated phase.